Skip to Main Content

Paper Details

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.
JCI Insight
12
2020
Author NameAffiliation
David K CrossmanUniversity of Alabama at Birmingham
David K CrossmanUniversity of Alabama at Birmingham
Robert S WelnerUniversity of Alabama at Birmingham
Robert S WelnerUniversity of Alabama at Birmingham
  • 1 - 4

Datasets

Release 1.2